Levamisole

Levamisole
Skeletal formula of levamisole
Ball-and-stick model of the levamisole molecule
Clinical data
Trade namesErgamisol, others
AHFS/Drugs.comMicromedex Detailed Consumer Information
MedlinePlusa697011
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status
  • Rx-only (RU)
Pharmacokinetic data
MetabolismLiver
Elimination half-life3–4 hours
ExcretionKidney (70%)
Identifiers
  • (S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b] [1,3]thiazole
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.035.290
Chemical and physical data
FormulaC11H12N2S
Molar mass204.29 g·mol−1
3D model (JSmol)
Density1.31 g/cm3
Melting point60 °C (140 °F)
Solubility in water210hydrochloride
  • N\2=C1/SCCN1C[C@@H]/2c3ccccc3
  • InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1
  • Key:HLFSDGLLUJUHTE-SNVBAGLBSA-N

Levamisole, sold under the brand name Ergamisol among others, is a medication used to treat parasitic worm infections, specifically ascariasis and hookworm infections. It is taken by mouth.

Side effects may include abdominal pain, vomiting, headache, and dizziness. Use is not recommended during breastfeeding or the third trimester of pregnancy. Serious side effects may include an increased risk of infection. It belongs to the anthelmintic class of medications.

Levamisole was invented in 1966 in Belgium by Janssen Pharmaceuticals. It is on the World Health Organization's List of Essential Medicines. Levamisole is also used as a dewormer for cattle. It is also often used as a cutting agent in illegal cocaine.

In February 2026, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended that medicines containing levamisole be withdrawn from the EU market. This follows an EU-wide review which concluded that the benefits of these medicines no longer outweigh their risks for the treatment of parasitic worm infections in adults and children.